Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Equities researchers at HC Wainwright issued their FY2026 earnings per share estimates for Travere Therapeutics in a research report issued on Tuesday, November 3rd. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.90) per share for the year. HC Wainwright has a “Buy” rating and a $67.00 price objective on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Travere Therapeutics’ Q4 2026 earnings at $0.39 EPS, FY2027 earnings at $2.14 EPS, FY2028 earnings at $4.43 EPS, FY2029 earnings at $5.17 EPS and FY2030 earnings at $6.84 EPS.
Other equities analysts also recently issued reports about the stock. Guggenheim cut their price target on shares of Travere Therapeutics from $89.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday. Canaccord Genuity Group upped their price objective on shares of Travere Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler reaffirmed an “overweight” rating on shares of Travere Therapeutics in a report on Monday, August 17th. TD Cowen lifted their target price on shares of Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Wedbush reiterated an “outperform” rating and issued a $76.00 target price on shares of Travere Therapeutics in a research note on Tuesday, September 22nd. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $68.60.
Read Our Latest Analysis on TVTX
Travere Therapeutics Stock Up 6.1%
TVTX opened at $52.42 on Thursday. The firm has a market cap of $5.03 billion, a price-to-earnings ratio of -40.64 and a beta of 1.11. The company has a debt-to-equity ratio of 26.72, a quick ratio of 3.99 and a current ratio of 3.00. The firm’s 50-day simple moving average is $58.12 and its 200-day simple moving average is $46.79. Travere Therapeutics has a twelve month low of $22.59 and a twelve month high of $68.73.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.49). Travere Therapeutics had a negative net margin of 18.66% and a negative return on equity of 185.69%. The company had revenue of $224.56 million for the quarter, compared to the consensus estimate of $195.29 million. During the same period in the previous year, the business posted $0.28 earnings per share. The firm’s revenue was up 36.2% compared to the same quarter last year.
Insider Buying and Selling
In related news, EVP Jula Inrig sold 44,674 shares of Travere Therapeutics stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total value of $2,784,977.16. Following the completion of the transaction, the executive vice president directly owned 100,491 shares of the company’s stock, valued at $6,264,608.94. The trade was a 30.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Dube sold 243,735 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $53.82, for a total transaction of $13,117,817.70. Following the transaction, the chief executive officer owned 432,886 shares in the company, valued at approximately $23,297,924.52. This trade represents a 36.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,294,029 shares of company stock valued at $79,454,261 in the last 90 days. 4.44% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Travere Therapeutics
Institutional investors have recently modified their holdings of the stock. Jupiter Topco LLC bought a new stake in shares of Travere Therapeutics during the second quarter worth $643,299,000. Bank of America Corp DE bought a new position in Travere Therapeutics in the second quarter valued at about $259,527,000. Assenagon Asset Management S.A. boosted its holdings in Travere Therapeutics by 168.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,145,414 shares of the company’s stock valued at $67,442,000 after acquiring an additional 718,109 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Travere Therapeutics by 50.0% in the second quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company’s stock valued at $87,094,000 after acquiring an additional 510,808 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in Travere Therapeutics in the second quarter worth about $26,723,000.
Travere Therapeutics News Roundup
Here are the key news stories impacting Travere Therapeutics this week:
- Positive Sentiment: Canaccord Genuity raised its price target to $72 from $70 and reiterated a Buy rating, signaling continued confidence in the stock’s potential. Canaccord Genuity recommendations
- Neutral Sentiment: Guggenheim lowered its target to $78 from $89 but maintained a Buy rating, leaving its outlook positive while reflecting a more cautious valuation. Guggenheim recommendations
- Neutral Sentiment: A recent technical analysis noted TVTX rebounded after reaching its 200-day moving average, a level investors may view as support. Travere’s 200-day moving average reversal
- Negative Sentiment: Travere’s third-quarter results showed a loss, despite higher revenue, adding a fundamental concern alongside analyst optimism. Travere Q3 results
Travere Therapeutics Company Profile
Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.
Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.
Featured Articles
- Five stocks we like better than Travere Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
